Format

Send to

Choose Destination
CNS Oncol. 2019 Jun;8(2):CNS34. doi: 10.2217/cns-2018-0015. Epub 2019 Mar 11.

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors.

Author information

1
Department of Neurosciences, University of California San Diego Moores Cancer Center, San Diego, CA, USA.
2
Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
3
Department of Medical Affairs, Guardant Health, Redwood City, CA, USA.

Abstract

Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.

KEYWORDS:

Guardant360; cell-free DNA; ctDNA; genomic profiling; glioblastoma; liquid biopsy; personalized medicine; primary brain tumors

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center